TABLE 2.

Oral Anticoagulation Contraindication Status and Outcomes Over 3 Years in Patients With Prevalent AF Who Were Not on OAC Medication (n = 26,684)

	Event Rate Percentage at 3 Yrs*			Unadjusted	Adjusted†
Outcome	No Contraindication (n = 18,401)	Contraindication (n = 8,283)	p Value	HR (95% CI)	HR (95% CI)	p Value
Death	34.6	49.6	<0.001	1.64 (1.57–1.70)	1.17 (1.12–1.22)	<0.001
Stroke-broad	10.1	11.3	0.003	1.28 (1.18–1.39)	1.01 (0.93–1.10)	0.83
Ischemic stroke	5.64	6.04	0.195	1.22 (1.09–1.36)	0.98 (0.87–1.10)	0.70
TIA	2.28	2.74	0.025	1.38 (1.17–1.62)	1.08 (0.91–1.29)	0.37
ICH	1.82	2.03	0.227	1.29 (1.06–1.55)	1.08 (0.89–1.32)	0.44
GI bleed-transfusion‡	0.42	0.99	<0.001	2.70 (1.96–3.72)	2.31 (1.64–3.24)	<0.001
Hospitalization	63.1	74.1	<0.001	1.53 (1.48–1.58)	1.20 (1.16–1.24)	<0.001

^*The death event rate p value is from the log-rank test. All other outcome event rate p values are from Gray’s tests.

^†Adjusted for age, race, gender, region, implantable device (ICD and cardiac resynchronization therapy with defibrillator), and comorbidities (atrial flutter, dementia, diabetes, coronary heart disease, peripheral vascular disease, congestive heart failure, cardiovascular disease, hypertension, COPD, renal disease, prior stroke, cancer, and valvular heart disease).

^‡Required a blood transfusion.

CI = confidence interval; HR = hazard ratio; other abbreviations as in Table 1.